Brilliant Violet 421™ anti-mouse CD86
Description
CD86 is an 80 kD immunoglobulin superfamily member also known as B7-2, B70, and Ly-58. CD86 is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. CD86, along with CD80, is a ligand of CD28 and CD152 (CTLA-4). CD86 is expressed earlier in the immune response than CD80. CD86 has also been shown to be involved in immunoglobulin class-switching and triggering of NK cell-mediated cytotoxicity. CD86 binds to CD28 to transduce co-stimulatory signals for T cell activation, proliferation, and cytokine production. CD86 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
References
1. Hathcock KS, et al. 1993. Science 262:905. (Block, IP)
2. Inaba KM, et al. 1994. J. Exp. Med. 180:1849. (Block, IHC)
3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
4. Krummel MF, et al. 1995. J. Exp. Med. 182:459. (Block)
5. Liu Y, et al. 1997. J. Exp. Med. 185:251. (Block)
6. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
8. Lawson BR, et al. 2007. J. Immunol. 178:5366.
9. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
10. Klinger MB, et al. 2007. Am. J. Physiol. Requl. Integr. Comp. Physiol. 293:R677. PubMed